On Thursday, Shares of Hewlett-Packard Company (NYSE:HPQ), gained 0.56% to $30.69.
Hewlett-Packard Company, declared that Hewlett Packard Enterprise Company filed an initial Registration Statement on Form 10 with the Securities and Exchange Commission (“SEC”). The filing of the Form 10 is an important step in HP’s plan to separate into two independent public companies: Hewlett Packard Enterprise Company and HP Inc. The filing provides detailed information on the business and historical financial results of Hewlett Packard Enterprise and will be updated with additional information in subsequent amendments as part of the SEC review process.
Additional information on the strategy and financial performance of both companies will be offered at HP’s Securities Analyst Meeting on September 15, 2015, in the San Francisco Bay Area.
Hewlett-Packard Company, together with its auxiliaries, provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to the government, health, and education sectors worldwide.
Shares of Chevron Corporation (NYSE:CVX), declined -0.23% to $95.87, during its last trading session.
Chevron Corporation, will hold its quarterly earnings conference call on Friday, July 31, 2015, at 11:00 a.m. ET (8:00 a.m. PT).
The meeting replay will also be accessible on the company website under the “Investors” section.
Chevron Corporation, through its auxiliaries, engages in the petroleum, chemicals, and power and energy operations worldwide. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, and production of crude oil and natural gas.
Finally, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ended its last trade with -1.69% loss, and closed at $6.97.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, declared that Valeant presented a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The companys primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
